Sanofi India Limited [SANOFI] vs Alembic [APLLTD] Detailed Stock Comparison
Sanofi India Limited
NSE
Loading...
Alembic
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sanofi India Limited wins in 12 metrics, Alembic wins in 8 metrics, with 0 ties. Sanofi India Limited appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sanofi India Limited | Alembic | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 32.36 | 30.86 | Alembic |
| Price-to-Book Ratio | 14.99 | 3.58 | Alembic |
| Debt-to-Equity Ratio | 2.67 | 24.23 | Sanofi India Limited |
| PEG Ratio | -0.99 | 2.09 | Sanofi India Limited |
| EV/EBITDA | 22.90 | 19.19 | Alembic |
| Profit Margin (TTM) | 18.29% | 8.84% | Sanofi India Limited |
| Operating Margin (TTM) | 21.12% | 12.13% | Sanofi India Limited |
| EBITDA Margin (TTM) | 21.12% | 12.13% | Sanofi India Limited |
| Return on Equity | 49.43% | 11.24% | Sanofi India Limited |
| Return on Assets (TTM) | 22.47% | 7.51% | Sanofi India Limited |
| Free Cash Flow (TTM) | $4.25B | $-4.76B | Sanofi India Limited |
| Dividend Yield | 1.93% | 1.09% | Sanofi India Limited |
| 1-Year Return | -29.00% | -21.60% | Alembic |
| Price-to-Sales Ratio (TTM) | 5.92 | 2.73 | Alembic |
| Enterprise Value | $114.31B | $197.77B | Alembic |
| EV/Revenue Ratio | 5.77 | 2.90 | Alembic |
| Gross Profit Margin (TTM) | 48.63% | 76.18% | Alembic |
| Revenue per Share (TTM) | $860 | $347 | Sanofi India Limited |
| Earnings per Share (Diluted) | $157.30 | $30.67 | Sanofi India Limited |
| Beta (Stock Volatility) | 0.07 | 0.47 | Sanofi India Limited |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sanofi India Limited vs Alembic Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sanofi India Limited | -0.24% | -0.65% | -2.33% | -17.64% | -10.28% | -16.57% |
| Alembic | 0.08% | 0.49% | 1.19% | -4.29% | 14.76% | -9.69% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sanofi India Limited | -29.00% | -16.12% | -40.08% | 21.40% | 179.52% | 247.09% |
| Alembic | -21.60% | 55.32% | -1.69% | 40.68% | 1,937.20% | 1,937.20% |
News Based Sentiment: Sanofi India Limited vs Alembic
Sanofi India Limited
News based Sentiment: MIXED
Sanofi India faced conflicting signals this month, with a 'Sell' rating from MarketsMOJO due to declining profits offset by continued positive analyst recommendations and a strong fundamental ranking. This creates a mixed investment picture, requiring investors to weigh short-term concerns against long-term potential.
Alembic
News based Sentiment: MIXED
Alembic Pharmaceuticals is showing a mixed bag of results this month. While long-term investor returns are strong and the company is maintaining dividend payments, a recent share price decline and slower revenue growth compared to the market create some uncertainty. The analyst meet should provide more clarity.
Performance & Financial Health Analysis: Sanofi India Limited vs Alembic
| Metric | SANOFI | APLLTD |
|---|---|---|
| Market Information | ||
| Market Cap | ₹117.32B | ₹186.08B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 6,257 | 76,905 |
| 90 Day Avg. Volume | 10,363 | 90,896 |
| Last Close | ₹5,078.50 | ₹947.30 |
| 52 Week Range | ₹4,902.00 - ₹7,490.00 | ₹725.20 - ₹1,303.90 |
| % from 52W High | -32.20% | -27.35% |
| All-Time High | ₹10,524.95 (Jun 10, 2024) | ₹1,303.90 (Oct 07, 2024) |
| % from All-Time High | -51.75% | -27.35% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.12% | 0.10% |
| Quarterly Earnings Growth | -0.33% | 0.15% |
| Financial Health | ||
| Profit Margin (TTM) | 0.18% | 0.09% |
| Operating Margin (TTM) | 0.21% | 0.12% |
| Return on Equity (TTM) | 0.49% | 0.11% |
| Debt to Equity (MRQ) | 2.67 | 24.23 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹339.62 | ₹264.09 |
| Cash per Share (MRQ) | ₹135.75 | ₹4.25 |
| Operating Cash Flow (TTM) | ₹3.90B | ₹-3,101,700,000 |
| Levered Free Cash Flow (TTM) | ₹2.49B | ₹5.83B |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.93% | 1.09% |
| Last 12-Month Dividend | ₹117.00 | ₹11.00 |
Valuation & Enterprise Metrics Analysis: Sanofi India Limited vs Alembic
| Metric | SANOFI | APLLTD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 32.36 | 30.86 |
| Forward P/E | 24.98 | 21.76 |
| PEG Ratio | -0.99 | 2.09 |
| Price to Sales (TTM) | 5.92 | 2.73 |
| Price to Book (MRQ) | 14.99 | 3.58 |
| Market Capitalization | ||
| Market Capitalization | ₹117.32B | ₹186.08B |
| Enterprise Value | ₹114.31B | ₹197.77B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.77 | 2.90 |
| Enterprise to EBITDA | 22.90 | 19.19 |
| Risk & Other Metrics | ||
| Beta | 0.07 | 0.47 |
| Book Value per Share (MRQ) | ₹339.62 | ₹264.09 |
Financial Statements Comparison: Sanofi India Limited vs Alembic
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SANOFI | APLLTD |
|---|---|---|
| Revenue/Sales | ₹5.36B | ₹17.11B |
| Cost of Goods Sold | ₹2.41B | ₹4.07B |
| Gross Profit | ₹2.95B | ₹13.03B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹1.62B | ₹2.08B |
| EBITDA | ₹1.75B | ₹2.87B |
| Pre-Tax Income | ₹1.65B | ₹1.90B |
| Income Tax | ₹458.00M | ₹364.80M |
| Net Income (Profit) | ₹1.20B | ₹1.54B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SANOFI | APLLTD |
|---|---|---|
| Cash & Equivalents | ₹2.84B | ₹834.80M |
| Total Current Assets | ₹11.27B | ₹40.88B |
| Total Current Liabilities | ₹7.19B | ₹24.12B |
| Long-Term Debt | ₹140.00M | ₹467.70M |
| Total Shareholders Equity | ₹8.61B | ₹51.90B |
| Retained Earnings | ₹4.46B | ₹43.94B |
| Property, Plant & Equipment | ₹3.11B | ₹4.45B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SANOFI | APLLTD |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SANOFI | APLLTD |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 6,257 | 76,905 |
| Average Daily Volume (90 Day) | 10,363 | 90,896 |
| Shares Outstanding | 23.03M | 196.56M |
| Float Shares | 9.07M | 57.33M |
| % Held by Insiders | 0.61% | 0.71% |
| % Held by Institutions | 0.26% | 0.17% |
Dividend Analysis & Yield Comparison: Sanofi India Limited vs Alembic
| Metric | SANOFI | APLLTD |
|---|---|---|
| Last 12-Month Dividend | ₹117.00 | ₹11.00 |
| Last 12-Month Dividend Yield | 1.93% | 1.09% |
| 3-Year Avg Annual Dividend | ₹220.00 | ₹13.33 |
| 3-Year Avg Dividend Yield | 2.07% | 1.17% |
| 3-Year Total Dividends | ₹660.00 | ₹40.00 |
| Ex-Dividend Date | Apr 25, 2025 | Jul 29, 2025 |